Severe cutaneous adverse rxns up in allopurinol initiators

April 23, 2013
Severe cutaneous adverse rxns up in allopurinol initiators
Allopurinol initiators have an almost 10-fold increased risk of severe cutaneous adverse reactions compared with nonusers, according to a study published in the April issue of Arthritis Care & Research.

(HealthDay)—Allopurinol initiators have an almost 10-fold increased risk of severe cutaneous adverse reactions (SCARs) compared with nonusers, according to a study published in the April issue of Arthritis Care & Research.

Seoyoung C. Kim, M.D., from Brigham and Women's Hospital in Boston, and colleagues conducted a propensity-score matched cohort study using data from five large Medicaid programs to examine the incidence rate and in-hospital mortality of hospitalization for in allopurinol initiators compared with non-allopurinol users.

During 65,625 person-years of follow-up for allopurinol initiators, the researchers found that 45 patients were hospitalized for SCARs, with a crude incidence ratio of 0.69 per 1,000 person-years. All cases occurred within 365 of initiating treatment with allopurinol and 91.1 percent occurred within 180 days. During the hospitalization, 26.7 percent of patients died. For non-allopurinol users, the crude incidence rate was 0.04 per 1,000 person-years. For allopurinol initiators versus nonusers, the risk of SCARs was significantly increased (hazard ratio, 9.68). After adjustment for age, comorbidities, and recent diuretic use, the hazard ratio for high-dosage (>300 mg/day) versus low-dosage allopurinol was 1.30 for allopurinol users.

"Our study suggests that the risk of SCARs was 10 times as high in allopurinol initiators as compared to non-allopurinol users," the authors write. "Future studies using a large detailed clinical data set from a large prospective inception cohort of users is needed for a better understanding of other risk factors of SCARs such as impaired renal function and concomitant medication use."

Several authors disclosed financial ties to pharmaceutical companies, including Takeda, which partially funded the study.

Explore further: Gout drug offers hope for heart disease patients

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Gout drug offers hope for heart disease patients

March 5, 2013
(Medical Xpress)—Research at the University of Dundee has shown than an old, inexpensive anti-gout drug has benefits for heart disease sufferers and has the potential to one day help prevent heart disease, sudden deaths ...

Post-SES implantation, statins prevent late revascularization

May 12, 2012
(HealthDay) -- For patients who undergo sirolimus-eluting stent (SES) implantation, use of statin therapy is associated with a reduced risk of late target lesion revascularization (TLR), according to a study published in ...

Recommended for you

Scientists find key proteins control risk of osteoarthritis during aging

February 14, 2018
More than 30 million Americans suffer from osteoarthritis making it one of the most common age-related diseases.

Acute treatment suppresses posttraumatic arthritis in ankle injury

February 7, 2018
A University of Iowa study has identified a method for inhibiting the occurrence of an aggressive form of arthritis that frequently develops following a severe traumatic injury. The preclinical work demonstrates the potential ...

Small molecule could make a big difference for arthritis patients

February 7, 2018
Will there come a time when a patient with arthritis can forgo joint replacement surgery in favor of a shot? Keck School of Medicine of USC scientist Denis Evseenko, MD, PhD, has reason to be optimistic.

Study finds bacteria in milk linked to rheumatoid arthritis

January 30, 2018
A strain of bacteria commonly found in milk and beef may be a trigger for developing rheumatoid arthritis in people who are genetically at risk, according to a new study from the University of Central Florida.

Osteoarthritis could be treated as two diseases, scientists reveal

January 10, 2018
Scientists at The University of Manchester have discovered that most people with osteoarthritis can be subdivided into two distinct disease groups, with implications for diagnosis and drug development.

US arthritis prevalence is much higher than current estimates

November 27, 2017
New research indicates that the prevalence of arthritis in the United States has been substantially underestimated, especially among adults

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.